Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Journal of Medicinal Chemistry|November 11, 2017
Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) AntagonistSalvatore Di Maro, Francesco Saverio Di Leva, Anna Maria Trotta, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 6, 2018
Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicityAnna Maria Trotta, Sara Santagata, Serena Zanotta, et al.
Hepatology International|May 4, 2023
Hepatocellular carcinoma (HCC) tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) tumor microenvironmentSara Santagata, Giuseppina Rea, Daniela Castaldo, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|July 1, 2020
Disulfide Bond Replacement with 1,4- and 1,5-Disubstituted [1,2,3]-Triazole on C-X-C Chemokine Receptor Type 4 (CXCR4) Peptide Ligands: Small Changes that Make Big DifferencesStefano Tomassi, Anna Maria Trotta, Caterina Ieranò, et al.
Journal of Medicinal Chemistry|August 30, 2016
Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) AntagonistsSalvatore Di Maro, Anna Maria Trotta, Diego Brancaccio, et al.
Journal of Medicinal Chemistry|March 4, 2021
Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in TumorsAnna Maria Trotta, Michela Aurilio, Crescenzo D'Alterio, et al.
Cell Death & Disease|July 24, 2019
CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cellsCaterina Ieranò, Crescenzo D'Alterio, Simona Giarra, et al.
Cancers|July 26, 2020
New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal CancerCrescenzo D'Alterio, Antonella Zannetti, Anna Maria Trotta, et al.
British Journal of Cancer|May 4, 2024
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patientsSara Santagata, Giuseppina Rea, Anna Maria Bello, et al.
Frontiers in Immunology|August 8, 2022
Characterization of KRAS Mutational Regression in Oligometastatic PatientsAlessandro Ottaiano, Roberta Penta de Vera d'Aragona, Anna Maria Trotta, et al.
Pageof 4